Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4140790 | 0.90 | P2RX7 (0.63) | P2RX7 | |
| SCHEMBL4155031 | 0.88 | P2RX7 (0.49) | P2RX7PDPK1 | |
| SCHEMBL4144554 | 0.87 | P2RX7 (0.64) | P2RX7 | |
| SCHEMBL4141508 | 0.87 | P2RX7 (0.66) | P2RX7 | |
| SCHEMBL4144548 | 0.85 | P2RX7 (0.60) | P2RX7 | |
| SCHEMBL4157609 | 0.85 | P2RX7 (0.62) | P2RX7 | |
| SCHEMBL4991283 | 0.85 | P2RX7 (0.57) | P2RX7 | |
| SCHEMBL4140996 | 0.85 | P2RX7 (0.57) | P2RX7 | |
| SCHEMBL4140408 | 0.85 | P2RX7 (0.59) | P2RX7 | |
| SCHEMBL4140355 | 0.84 | P2RX7 (0.63) | P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090170838-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. | 2009-07-02 | — | — | US | claimed |
| US-7402596-B2 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. (US) | 2008-07-22 | — | — | US | claimed |
| EP-1865774-A1 | BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF | Renovis, Inc. (US) | 2007-12-19 | — | — | EP | claimed |
| US-20070197565-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. | 2007-08-23 | — | — | US | claimed |
| WO-2006102588-A1 | BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF | RENOVIS, INC. (US) | 2006-09-28 | — | — | WO | claimed |
| US-20090208415-A1 | Tropane compounds | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2009-08-20 | — | — | US | disclosed |
| US-20090170838-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. | 2009-07-02 | — | — | US | disclosed |
| US-20090170838-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. | 2009-07-02 | — | — | US | disclosed |
| US-7402596-B2 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. (US) | 2008-07-22 | — | — | US | disclosed |
| US-7402596-B2 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. (US) | 2008-07-22 | — | — | US | disclosed |
| US-20070197565-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. | 2007-08-23 | — | — | US | disclosed |
| US-20070197565-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197565-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | P2RX7, P2RX3, P2RX2 | P2RX7 1/4885PDPK1 504/4885 |
| US-20090208415-A1 | Tropane compounds | TPM3, TPM4, ADRA2C | P2RX7 841/4885PDPK1 4380/4885 |
| US-20090170838-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | P2RX7, P2RX3, P2RX2 | P2RX7 1/4885PDPK1 504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.